Please try another search
For the fiscal year ended 31 December 2021, Antares Pharma Inc revenues increased 23% to $184M. Net income decreased 18% to $46.3M. Revenues reflect Proprietary product sales segment increase of 27% to $80M, Royalties segment increase of 77% to $37.7M, United States of America segment increase of 22% to $178.3M, Europe segment increase of 49% to $5.7M. Net income was offset by Business development increase of 17% to $72.8M (expense).
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 48.73 | 48.19 | 44.98 | 42.08 |
Gross Profit | 29.76 | 31.76 | 28.54 | 25.64 |
Operating Income | 7.2 | 7.96 | 6.79 | 5.39 |
Net Income | 32.68 | 5.39 | 4.42 | 3.79 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 257.5 | 216.74 | 212.62 | 218.46 |
Total Liabilities | 81.75 | 75.91 | 80.59 | 92.23 |
Total Equity | 175.76 | 140.83 | 132.03 | 126.22 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 36.62 | 27.13 | 8.41 | 1.98 |
Cash From Investing Activities | -3.85 | -4.96 | -2.46 | -1.18 |
Cash From Financing Activities | -19.99 | -17.94 | -13.96 | 1.72 |
Net Change in Cash | 12.78 | 4.23 | -8.01 | 2.52 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review